Status:
COMPLETED
Learning to Live With Non-severe Haemophilia
Lead Sponsor:
Haemnet
Collaborating Sponsors:
BioMarin Pharmaceutical
Conditions:
Hemophilia
Eligibility:
MALE
16-100 years
Brief Summary
While the burden of standard treatment may be reduced through the use of gene therapy, converting those with severe haemophilia to a mild or moderate phenotype, the long-term sequelae of previous join...
Detailed Description
Haemophilia is a rare congenital disorder caused by an inherited genetic defect which affects approximately one in every 5,000 males. Haemophilia A (factor VIII \[FVIII\] deficiency) occurs in 85% of ...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of haemophilia A or B of any severity
Exclusion
- Diagnosis of any other bleeding disorder
Key Trial Info
Start Date :
December 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2023
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT05314751
Start Date
December 21 2022
End Date
September 29 2023
Last Update
March 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oxford University Hospitals NHS Foundation Trust
Oxford, Oxfordshire, United Kingdom, OX3 9DU